KALA BIO INC (KALA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.51-9.57%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · KALA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Effect a reverse stock split at a ratio of 1-for-50 to reduce outstanding shares and maintain Nasdaq listing compliance.
Newly stated in 2026-Q2 period via May 7, 2026 press release. The company executed a 1-for-50 reverse stock split reducing shares outstanding from approximately 929M to 18.6M to comply with Nasdaq listing rules. This is a one-time capital structure action with clear delivery.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Obtain and deploy an exclusive worldwide license for Younet's proprietary biomedical AI research platform to build AI infrastructure for biotech.
Newly stated in 2026-Q1 period. The company secured an exclusive worldwide license for Younet's AI platform as a strategic growth initiative. No financial metrics are available yet to assess delivery, but the agreement is executed.
Implement material modifications to the rights of security holders as part of capital allocation and restructuring efforts.
Newly stated in 2026-Q2 period. The company disclosed material modifications to security holder rights as part of capital allocation. No financial impact data is provided to assess progress.
Conduct unregistered sales of equity securities to raise capital as part of financing strategy.
Newly stated in 2026-Q1 period. The company disclosed unregistered equity sales as a capital raising measure. No specific financial amounts or outcomes are provided.
Over the trailing year it converted 1.17x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
41 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.